Oncology

Adding autologous tumor lysate-loaded dendritic cell vaccination to standard of care associated with clinical improvement in overall survival for patients with newly diagnosed and recurrent glioblastoma

Nov 28, 2022

1. In this phase 3 nonrandomized controlled trial, among 331 patients, patients with newly...

Characterization of negative outcomes associated with same-day cancellation of cancer surgeries

Nov 22, 2022

1. This retrospective study found that patients who experienced a same-day cancellation of their...

Association of quality and technology with patient mobility for colorectal cancer surgery

Nov 19, 2022

1. Around 30% of colorectal patients travel beyond their closest hospital site to undergo a...

First-line treatment with immune checkpoint inhibitor rather than BRAF and MEK leads to improved survival

Nov 11, 2022

1. Starting treatment with nivolumab/ipilimumab rather than dabrafenib/trametinib resulted in an...

Second-line immunosuppression associated with worse outcomes for immune-related adverse events in melanoma

Nov 11, 2022

1. Median overall survival was longer in patients receiving steroid-only treatment for adverse...

United States-based chemotherapy regimen for Ewing sarcoma is more effective and safer than the standard European regimen

Nov 11, 2022

1. The United States regimen had greater event-free survival and less associated febrile...

The experience of spirituality may positively impact the lives of terminal cancer patients

Oct 31, 2022

1. In this study, individuals were found to experience peace at the end of life through...

Variation in prostate cancer screening rates associated with subsequent metastatic prostate cancer incidence

Oct 31, 2022

1. A retrospective analysis demonstrated that prostate-specific antigen (PSA) screening has...

Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival

Oct 25, 2022

1. The median progression-free survival was higher in the enzalutamide vs the placebo group (9.5...

Adjuvant pembrolizumab improved distant-metastasis free survival and lowered risk of recurrence in melanoma patients

Oct 25, 2022

1. In the pembrolizumab arm, distant metastasis-free survival was significantly improved and the...

Polycystic ovarian syndrome is associated with an increased risk of pancreatic cancer

Oct 21, 2022

1. Polycystic ovarian syndrome (PCOS) diagnosis puts women at 1.9 times higher risk of pancreatic...

Adding weightlifting exercises may further reduce risk of mortality

Oct 21, 2022

1. After adjusting for aerobic moderate to vigorous physical activity (MVPA), weightlifting was...

Fine needle biopsy remains a reliable test for thyroid cancer diagnosis

Oct 21, 2022

1. In this systematic review and meta-analysis that included 16,597 patients, fine needle biopsy...

Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma

Oct 15, 2022

1. Atezolizumab was associated with non-significantly increased disease-free survival compared to...

Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

Oct 15, 2022

1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab...

Optimized vitamin C levels may be associated with mitigated HPV infection risk

Oct 15, 2022

1. Though not statistically significant, there was a U-shaped found between vitamin C levels and...

Stereotactic body radiation does not improve outcomes in patients with advanced Merkel cell carcinoma receiving nivolumab and ipilimumab

Oct 11, 2022

1. Objective response rate was not significantly different in patients treated with stereotactic...

Ipilimumab addition to nivolumab showed no significant clinical benefit in resected advanced stage melanoma

Oct 11, 2022

Ipilimumab addition to nivolumab showed no significant clinical benefit in resected advanced stage...

Letrozole and abemaciclib in estrogen receptor–positive recurrent endometrial cancer

Oct 11, 2022

1. Almost half of patients (47%) had either an objective response or had progression free survival...

Fulvestrant for treatment of estrogen receptor-positive, HER2-negative advanced breast cancer may improve progression free survival using ESR1 mutation as guidance

Oct 11, 2022

1. Median progression free survival was longer in the fulvestrant and palbociclib group compared...

Follow Us

Oncology